Life Sciences Investor Forum
Coiled Therapeutics plc announced that its Chairman will present at the Life Sciences Investor Forum on June 25, 2026, providing an opportunity for investors to engage with management. The company, listed on AIM and OTCQB, is a clinical-stage oncology firm developing precision medicines, with its lead program AO-252, a TACC3 inhibitor, currently in Phase I trials for hard-to-treat cancers. The presentation will likely cover updates on the ongoing clinical trials and the company's strategic direction.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that the Company's Chairman Sotirios Stergiopoulos will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on 25 June 2026.
DATE: 25 June 2026
TIME: 18:30 BST / 13.30pm Eastern Time
LINK: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389896/coiled-therapeutics-plc-otcqb-cotxf-aim-coil
The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.
Investors can learn more about the event at www.virtualinvestorconferences.com.
About AO-252
By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, a key differentiator that may enable treatment of both primary brain tumours and brain metastases, areas of significant unmet medical need. Preclinical and early clinical observations support further evaluation of the programme's potential across multiple tumour types.
AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study in the United States. Early clinical observations have demonstrated encouraging anti-tumour activity and a favourable safety profile, with the Company planning to initiate dose expansion cohorts in selected indications, including prostate and ovarian cancer, during 2026.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.